Payment overview · 2025
General Payments
$29.71
1 reported records · 1 companies
Healthcare provider profile · identity verified
Mark Charles Howard, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SAINT LOUIS, MO · NPI 1073586848
Verified facts
What the public records show
CMS Open Payments records show Mark Charles Howard, MD received $29.71 in general payments during 2025 across 1 reported records.
GlaxoSmithKline, LLC. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $29.71 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $29.71 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $29.71 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $29.71 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 50 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
50 | 50 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 838 | 221 |
| Amlodipine Besylate | Amlodipine Besylate | 550 | 144 |
| Lisinopril | Lisinopril | 485 | 143 |
| Losartan Potassium | Losartan Potassium | 475 | 123 |
| Levothyroxine Sodium | Levothyroxine Sodium | 466 | 118 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 421 | 127 |
| Simvastatin | Simvastatin | 363 | 97 |
| Omeprazole | Omeprazole | 346 | 103 |
| Tamsulosin Hcl | Tamsulosin Hcl | 346 | 93 |
| Metoprolol Succinate | Metoprolol Succinate | 313 | 93 |
| Metformin Hcl | Metformin Hcl | 311 | 82 |
| Gabapentin | Gabapentin | 301 | 87 |
| Pantoprazole Sodium | Pantoprazole Sodium | 238 | 66 |
| Alprazolam | Alprazolam | 205 | 52 |
| Tramadol Hcl | Tramadol Hcl | 178 | 58 |
| Furosemide | Furosemide | 177 | 49 |
| Sertraline Hcl | Sertraline Hcl | 177 | 44 |
| Finasteride | Finasteride | 170 | 43 |
| Allopurinol | Allopurinol | 169 | 44 |
| Eliquis | Apixaban | 168 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 164 | 48 |
| Trazodone Hcl | Trazodone Hcl | 164 | 44 |
| Potassium Chloride | Potassium Chloride | 157 | 36 |
| Zolpidem Tartrate | Zolpidem Tartrate | 157 | 45 |
| Alendronate Sodium | Alendronate Sodium | 148 | 50 |
| Meloxicam | Meloxicam | 147 | 50 |
| Mirtazapine | Mirtazapine | 145 | 36 |
| Bupropion Xl | Bupropion Hcl | 136 | 32 |
| Pravastatin Sodium | Pravastatin Sodium | 132 | 32 |
| Metformin Hcl Er | Metformin Hcl | 127 | 36 |
| Fluoxetine Hcl | Fluoxetine Hcl | 119 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 118 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 118 | 32 |
| Famotidine | Famotidine | 114 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 109 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 109 | 45 |
| Escitalopram Oxalate | Escitalopram Oxalate | 105 | 28 |
| Buspirone Hcl | Buspirone Hcl | 103 | 20 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 96 | 28 |
| Ezetimibe | Ezetimibe | 90 | 25 |
| Carvedilol | Carvedilol | 87 | 27 |
| Jardiance | Empagliflozin | 85 | 23 |
| Spironolactone | Spironolactone | 84 | 26 |
| Donepezil Hcl | Donepezil Hcl | 83 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 77 | 24 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 77 | 20 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 73 | 25 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 73 | 17 |
| Atenolol | Atenolol | 72 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 72 | 20 |
| Trulicity | Dulaglutide | 70 | 11 |
| Enalapril Maleate | Enalapril Maleate | 64 | 15 |
| Prednisone | Prednisone | 63 | 41 |
| Tizanidine Hcl | Tizanidine Hcl | 62 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 61 | 19 |
| Glipizide Er | Glipizide | 57 | 16 |
| Ipratropium Bromide | Ipratropium Bromide | 57 | 19 |
| Montelukast Sodium | Montelukast Sodium | 55 | 19 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 54 | 42 |
| Lorazepam | Lorazepam | 53 | 11 |
| Ozempic | Semaglutide | 52 | suppressed |
| Celecoxib | Celecoxib | 51 | 12 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 50 | 50 |
| Azelastine Hcl | Azelastine Hcl | 50 | 22 |
| Januvia | Sitagliptin Phosphate | 50 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 50 | suppressed |
| Glipizide | Glipizide | 49 | 13 |
| Fenofibrate | Fenofibrate | 48 | 13 |
| Synthroid | Levothyroxine Sodium | 48 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 45 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 44 | 22 |
| Acyclovir | Acyclovir | 42 | 14 |
| Pregabalin | Pregabalin | 41 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 40 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 40 | 16 |
| Xarelto | Rivaroxaban | 40 | suppressed |
| Cephalexin | Cephalexin | 39 | 23 |
| Diazepam | Diazepam | 39 | 12 |
| Methylprednisolone | Methylprednisolone | 39 | 38 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 39 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 38 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 37 | 34 |
| Doxazosin Mesylate | Doxazosin Mesylate | 36 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 35 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 33 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 33 | suppressed |
| Baclofen | Baclofen | 32 | suppressed |
| Primidone | Primidone | 32 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 31 | suppressed |
| Irbesartan | Irbesartan | 31 | suppressed |
| Azithromycin | Azithromycin | 30 | 29 |
| Testosterone Cypionate | Testosterone Cypionate | 30 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | suppressed |
| Calcitriol | Calcitriol | 26 | suppressed |
| Mupirocin | Mupirocin | 26 | 16 |
| Myrbetriq | Mirabegron | 26 | suppressed |
| Glimepiride | Glimepiride | 25 | suppressed |
| Memantine Hcl | Memantine Hcl | 25 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Torsemide | Torsemide | 24 | suppressed |
| Clonazepam | Clonazepam | 23 | suppressed |
| Estradiol | Estradiol | 23 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 23 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 22 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 22 | suppressed |
| Naproxen | Naproxen | 22 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 22 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 20 |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 21 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Temazepam | Temazepam | 21 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 19 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 19 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 19 | suppressed |
| Klor-Con M20 | Potassium Chloride | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Methocarbamol | Methocarbamol | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 17 | 17 |
| Indapamide | Indapamide | 17 | suppressed |
| Nystatin | Nystatin | 17 | 11 |
| Ramipril | Ramipril | 17 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 16 | suppressed |
| Clotrimazole | Clotrimazole | 16 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 14 |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Repatha Sureclick | Evolocumab | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 12 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 14 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Acarbose | Acarbose | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Glyburide | Glyburide | 13 | suppressed |
| Loperamide | Loperamide Hcl | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Testosterone | Testosterone | 11 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $29.71 · 1 records | GlaxoSmithKline, LLC. | AREXVY, SHINGRIX | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error